The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2007-06-092122PMID 18156491PMCID PMC2265454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

  2008cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis

  2007cited by this paper
• Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2

  2006cited by this paper
• A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling

  2006cited by this paper
• Regulation of LSD1 histone demethylase activity by its associated factors.

  2005cited by this paper
• Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

  2005cited by this paper
• Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma

  2005cited by this paper
• CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus

  2005cited by this paper
• The theoretical basis of transcriptional therapy of cancer: can it be put into practice?

  2005cited by this paper
• Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

  2005cited by this paper
• Chromatin Targeting of de Novo DNA Methyltransferases by the PWWP Domain

  2005cited by this paper
• Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.

  2004cited by this paper
• CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription.

  2004cited by this paper
• Chromatin Targeting of de Novo DNA Methyltransferases by the PWWP Domain*

  2004cited by this paper
• A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin.

  2004cited by this paper
• Ligand-dependent Activation of the Farnesoid X-receptor Directs Arginine Methylation of Histone H3 by CARM1*

  2004cited by this paper
• The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

  2004cited by this paper
• A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma

  2004cited by this paper
• NSD1 is essential for early post‐implantation development and has a catalytically active SET domain

  2003cited by this paper
• A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.

  2003cited by this paper
• Growth Suppression by Acute PromyelocyticLeukemia-Associated Protein PLZF Is Mediated by Repression ofc-mycExpression

  2003cited by this paper
• Tools for comparative protein structure modeling and analysis

  2003cited by this paper
• In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

  2003influential reference
• Structure and catalytic mechanism of the human histone methyltransferase SET7/9

  2003cited by this paper
• Active genes are tri-methylated at K4 of histone H3

  2002cited by this paper
• MLL targets SET domain methyltransferase activity to Hox gene promoters.

  2002cited by this paper
• Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

  2002cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002cited by this paper
• NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• SET Domain-containing Protein, G9a, Is a Novel Lysine-preferring Mammalian Histone Methyltransferase with Hyperactivity and Specific Selectivity to Lysines 9 and 27 of Histone H3*

  2001influential reference
• Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase.

  2001cited by this paper
• A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription.

  2001cited by this paper
• Loss of HCF-1–Chromatin Association Precedes Temperature-Induced Growth Arrest of tsBN67 Cells

  2001cited by this paper
• Arrest of tsBN 67 Cells Precedes Temperature-Induced Growth Chromatin Association − Loss of HCF-1

  2001cited by this paper
• Regulation of chromatin structure by site-specific histone H3 methyltransferases

  2000cited by this paper
• Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.

  2000cited by this paper
• The PWWP domain: a potential protein–protein interaction domain in nuclear proteins influencing differentiation?

  2000cited by this paper
• The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

  1998cited by this paper
• WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma.

  1998cited by this paper
• Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression

  1997cited by this paper
• Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

  1996cited by this paper
• A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

  1991cited by this paper
• A vector for expressing GAL4(1-147) fusions in mammalian cells.

  1989cited by this paper

• NSD Family-Mediated H3K36 Methylation in Human Cancer: Mechanisms and Therapeutic Opportunities

  2025cites this paper
• NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway.

  2025cites this paper
• NSD proteins in anti-tumor immunity and their therapeutic targeting by protein degraders

  2025cites this paper
• Discovery of NSD2 non-histone substrates and design of a super-substrate

  2024cites this paper
• The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward

  2024cites this paper
• The oncogenic role of the NSD histone methyltransferases in head and neck and cervical cancers

  2024cites this paper
• Intestinal NSD2 Aggravates Nonalcoholic Steatohepatitis Through Histone Modifications

  2024cites this paper
• Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.

  2024cites this paper
• The C-terminal PHDVC5HCH tandem domain of NSD2 is a combinatorial reader of unmodified H3K4 and tri-methylated H3K27 that regulates transcription of cell adhesion genes in multiple myeloma

  2024cites this paper
• Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.

  2024cites this paper
• The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.

  2023cites this paper
• Outcomes with panobinostat in heavily pretreated multiple myeloma patients.

  2023cites this paper
• Stratification of Patients with Multiple Myeloma: State-of-the-Art and Prospects

  2022cites this paper
• The Role of Epigenetics in the Development and Progression of Multiple Myeloma

  2022cites this paper
• The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy

  2022cites this paper
• Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas.

  2022cites this paper
• The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

  2022cites this paper
• A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization

  2021cites this paper
• Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

  2021cites this paper
• Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications

  2021cites this paper
• Lysine methyltransferase inhibitors: where we are now

  2021cites this paper
• Multiple Myeloma: Molecular Pathogenesis and Disease Evolution

  2021cites this paper
• Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma

  2021cites this paper
• TACG_A_262866 241..254

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Disorders of sex development in Wolf–Hirschhorn syndrome: a genotype–phenotype correlation and MSX1 as candidate gene

  2021cites this paper
• SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma

  2021cites this paper
• Genetic Predictors of Mortality in Patients with Multiple Myeloma

  2021cites this paper
• Pharmacological targeting of a PWWP domain demonstrates cooperative control of NSD2 localization

  2021cites this paper
• The prognostic impact of tumour NSD2 expression in advanced prostate cancer

  2020cites this paper
• Epigenetic Aberrations in Multiple Myeloma

  2020cites this paper
• Clinical efficiency of epigenetic drugs therapy in bone malignancies.

  2020cites this paper
• H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres

  2020cites this paper
• Histone Deacetylation

  2020cites this paper
• NSD2 Gene

  2020cites this paper
• Histone lysine demethylase 3B (KDM3B) regulates the propagation of autophagy via transcriptional activation of autophagy-related genes

  2020cites this paper
• Regulatory mechanisms of B cell responses and the implication in B cell-related diseases

  2019cites this paper
• A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22)

  2019cites this paper
• Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

  2019cites this paper
• Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling

  2019cites this paper
• Histone 4 Lysine 20 Methylation: A Case for Neurodevelopmental Disease

  2019cites this paper
• Epigenetic Modification in Macrophages: A Promising Target for Tumor and Inflammation-associated Disease Therapy.

  2019cites this paper
• The Role of Histone Methylation and Methyltransferases in Gene Regulation

  2019cites this paper
• Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

  2019cites this paper
• The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response

  2018cites this paper
• Transcription-associated histone modifications & cryptictranscription

  2018cites this paper
• LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer

  2018cites this paper
• Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.

  2018cites this paper
• High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper
• Proteomic approaches for cancer epigenetics research

  2018cites this paper
• MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells

  2018cites this paper
• The biological significance of histone modifiers in multiple myeloma: clinical applications

  2018cites this paper
• Small Molecule Inhibitors of the Human Histone Lysine Methyltransferase NSD2 / WHSC1 / MMSET Identified from a Quantitative High-Throughput Screen with Nucleosome Substrate

  2017cites this paper
• Wolf-Hirschhorn Syndrome Candidate 1 Is Necessary for Correct Hematopoietic and B Cell Development.

  2017cites this paper
• MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis

  2017cites this paper
• Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

  2017influential citation
• The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

  2017cites this paper
• Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma

  2017cites this paper
• Epigenetics in multiple myeloma: From mechanisms to therapy.

  2017cites this paper
• Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

  2017cites this paper
• Necessary for Correct Hematopoietic and B Cell Development Graphical Abstract Highlights

  2017cites this paper
• Targeted Inhibition of Polycomb Repressive Complexes in Multiple Myeloma : Implications for Biology and Therapy

  2017cites this paper
• MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis.

  2017cites this paper
• Histone Methylation in Heart Development and Cardiovascular Disease

  2016cites this paper
• Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.

  2016cites this paper
• Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.

  2016cites this paper
• Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

  2016cites this paper
• Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

  2016cites this paper
• The biological function of Cancer-testis antigen MAGE-C2/CT10 in Multiple Myeloma

  2016cites this paper
• Small RNAs Recruit Chromatin-Modifying Enzymes MMSET and Tip60 to Reconfigure Damaged DNA upon Double-Strand Break and Facilitate Repair.

  2016cites this paper
• MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication

  2016cites this paper
• Epigenetics in Multiple Myeloma.

  2016cites this paper
• Approaches and Guidelines for the Identification of Novel Substrates of Protein Lysine Methyltransferases.

  2016cites this paper
• Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration

  2016cites this paper
• MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

  2015cites this paper
• RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20

  2015influential citation
• Multiple myeloma: is it time for biomarker-driven therapy?

  2015cites this paper
• Genomic heterogeneity in multiple myeloma.

  2015cites this paper
• Histone methylations in heart development, congenital and adult heart diseases.

  2015cites this paper
• Tumour Survival Signals and Epigenetic Gene Silencing in Multiple Myeloma : Implications for Biology and Therapy

  2015cites this paper
• Auditory hair cell defects as potential cause for sensorineural deafness in Wolf-Hirschhorn syndrome

  2015cites this paper
• DMM019547 1027..1035

  2015cites this paper
• Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention

  2015cites this paper
• Epigenetic modifiers in normal and malignant hematopoiesis.

  2015cites this paper
• MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib

  2015cites this paper
• MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

  2014cites this paper
• In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

  2014cites this paper
• A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex

  2014cites this paper
• NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel 1

  2014cites this paper
• The role of epigenetics in the biology of multiple myeloma

  2014cites this paper
• Pathogenesis of Multiple Myeloma

  2014cites this paper
• Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1.

  2014cites this paper
• In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L

  2014cites this paper
• Role of somatic cancer mutations in human protein lysine methyltransferases.

  2014cites this paper
• Epigenetics and Cardiovascular Disease

  2014cites this paper
• Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches

  2014cites this paper
• Understanding the language of Lys 36 methylation at histone H 3

  2014cites this paper
• Understanding the multiple biological aspects leading to myeloma

  2014cites this paper